A more widespread adoption of an approach taken by a new scheme in which payment for an anticancer drug is linked to treatment response might create stronger incentives and opportunities for the discovery and application of clinically relevant biomarkers.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Hughes, B. Novel risk-sharing scheme puts the spotlight on biomarkers. Nat Rev Drug Discov 6, 945 (2007). https://doi.org/10.1038/nrd2478
Issue date:
DOI: https://doi.org/10.1038/nrd2478
This article is cited by
-
Assessing the risks of risk sharing
Nature Reviews Drug Discovery (2010)
-
Developing tools for stratified medicine
Nature Reviews Drug Discovery (2009)
-
News in brief
Nature Reviews Drug Discovery (2009)
-
Biomarkers of response and resistance to antiangiogenic therapy
Nature Reviews Clinical Oncology (2009)
-
2007: Spotlight on drug safety
Nature Reviews Drug Discovery (2008)